Undifferentiated Pleomorphic Sarcoma Symptoms, Doctors, Treatments, Advances & More

Learn About Undifferentiated Pleomorphic Sarcoma

What is the definition of Undifferentiated Pleomorphic Sarcoma?

Undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma, is a rare, aggressive soft tissue or bone cancer that usually occurs in the arms or legs in the sixth or seventh decade of life.

Save information for later

What are the symptoms of Undifferentiated Pleomorphic Sarcoma?

Symptoms of undifferentiated pleomorphic sarcoma may include the presence of a mostly painless, rapidly enlarging nodule in the lower extremities (especially the thigh), upper arms, head and neck, retroperitoneum, viscera, distal or proximal femur (upper leg), proximal tibia (lower leg), or humerus (upper arm). Additional symptoms of undifferentiated pleomorphic sarcoma may include pain, swelling, malaise, lack of appetite, constipation, fever, and weight loss.

Not sure about your diagnosis?

Check Your Symptoms

What are the current treatments for Undifferentiated Pleomorphic Sarcoma?

Treatment for undifferentiated pleomorphic sarcoma depends on the location but may include surgery, radiation therapy, chemotherapy (ifosfamide, trabectedin, dacarbazine, and pazopanib), targeted therapy, and immunotherapy.

Who are the top Undifferentiated Pleomorphic Sarcoma Local Doctors?

Dr. Sandra P. Dangelo

Oncology

Elite

Highly rated in

conditions

Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave,

New York, NY

Sandra Dangelo is an Oncologist in New York, New York. Dangelo has been practicing medicine for over 19 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. She is also highly rated in 35 other conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Synovial Sarcoma, and Liver Embolization. Dangelo is currently accepting new patients.

Dr. Sonali M. Smith

Hematology Oncology | Hematology | Oncology

Elite

Highly rated in

conditions

Hematology Oncology
Hematology
Oncology

UChicago Medicine

Duchossois Center For Advanced Medicine (DCAM) - Hyde Park

5758 S Maryland Ave,

Chicago, IL

Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Smith has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. She is also highly rated in 34 other conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Smith is currently accepting new patients.

Learn about our expert tiers

Learn more

Dr. Anas Younes

Oncology

Elite

Highly rated in

conditions

Oncology

1275 York Ave,

New York, NY

Anas Younes is an Oncologist in New York, New York. Younes has been practicing medicine for over 40 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Classical Hodgkin Lymphoma, and Hodgkin Lymphoma.

View All Doctors

What are the latest Undifferentiated Pleomorphic Sarcoma Clinical Trials?

A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Who is this study for: Adult patients with Follicular Lymphoma or Marginal Zone Lymphoma

Enrollment Status: Recruiting

Publish Date: December 15, 2022

Intervention Type: Drug

Study Drugs: FludarabineCyclophosphamideCD4-Positive CAR-T Cells

Study Phase: Phase 2

Summary: This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirement...

Match to trials

Find the right clinical trials for you in under a minute

Get started

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Enrollment Status: Not yet recruiting

Publish Date: December 15, 2022

Intervention Type: Drug, Biological

Study Phase: Phase 1/Phase 2

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.

View All Clinical Trials

What are the Latest Advances for Undifferentiated Pleomorphic Sarcoma?